KEYNOTE 522 is the fourth study of a KEYTRUDA-based regimen in an earlier stage of cancer to demonstrate an OS benefit, in addition to KEYNOTE-A18 in cervical cancer, KEYNOTE-671 in non-small cell lung cancer and KEYNOTE-564 in...
BRCA1 patients had high rates of pCR regardless of treatment group, KEYNOTE-522: 80.0% (4/5) and control: 75% (9/12), (p= 1).#This real-world evidence supports the use of the KEYNOTE-522 regimen in patients with early-stage TNBC given the higher pCR rate and corresponding decrease...
And then I think it's very difficult not to incorporate immune therapy into a neoadjuvant treatment regimen if we show we significantly increase the path CR rates, but we also reduce recurrences, which are very closely linked with survival in triple negative breast cancer. Is data starting to ...
2、Gianni L, et al. Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. ESMO Congress 2023, LBA19 3、Loi S, et al...
Fig. 2: Schema for Modified KN522 + THP + Carbo Regimen. ddAC: Dose-dense doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) every 2 weeks; GCSF: granulocyte-colony stimulating factor, AKA peg-filgrastim; THP: weekly paclitaxel (80 mg/m2) and carboplatin (AUC 5) every...
KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the...
The dose-limiting toxicity evaluation period comprised treatment cycle 1 through the first two cycles of combination regimen 1 (i.e. from cycle 1, day 1 through the end of cycle 3) and the first two cycles of combination regimen 2 (i.e. from cycle 6, day 1 through the end of cycle ...
之前的Keynote522研究告诉我们PD-1单抗用于早期高危三阴型乳腺癌患者,新辅助治疗可提高pCR率(1),辅助治疗延长了无事件生存期(2),OS显示获益趋势。那么,它是否在晚期三阴乳腺癌中可以占有一席之地呢?最近发表于《新英格兰医学杂志》的结果表明,一线治疗局部复发不可手术或转移性三阴性乳腺癌患者,在PD-L1阳性综合...
The chemotherapy regimen chosen in this trial was what I would describe as the most effective chemotherapy regimen we have at the moment. That is really important, because the benefit of pembrolizumab, shown on top of that, is even more relevant....
“Together with the efficacy and safety findings of KEYNOTE-522, these PRO results support neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab as an effective standard-of-care treatment regimen in this setting, without meaningful impact on health-related quality of...